MCID: CNS004
MIFTS: 58

Constipation

Categories: Gastrointestinal diseases

Aliases & Classifications for Constipation

MalaCards integrated aliases for Constipation:

Name: Constipation 12 30 6 44 45 15

Classifications:



External Ids:

Disease Ontology 12 DOID:2089
ICD9CM 36 564.0 564.00
MeSH 45 D003248
NCIt 51 C37930
SNOMED-CT 69 14760008
ICD10 34 K59.0 K59.00
UMLS 74 C0009806

Summaries for Constipation

MedlinePlus : 44 Constipation means that a person has three or fewer bowel movements in a week. The stool can be hard and dry. Sometimes it is painful to pass. At one time or another, almost everyone gets constipated. In most cases, it lasts a short time and is not serious. There are many things you can do to prevent constipation. They include Eating more fruits, vegetables and grains, which are high in fiber Drinking plenty of water and other liquids Getting enough exercise Taking time to have a bowel movement when you need to Using laxatives only if your doctor says you should Asking your doctor if medicines you take may cause constipation It's not important that you have a bowel movement every day. If your bowel habits change, however, check with your doctor. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Constipation is related to intestinal pseudo-obstruction and intestinal obstruction. An important gene associated with Constipation is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Oxycodone and Naloxone have been mentioned in the context of this disorder. Affiliated tissues include colon, lung and breast, and related phenotypes are no effect and Decreased viability

Disease Ontology : 12 A bowel dysfunction that is characterized by infrequent or difficult evacuation of feces.

Wikipedia : 77 Constipation refers to bowel movements that are infrequent or hard to pass. The stool is often hard and... more...

Related Diseases for Constipation

Diseases related to Constipation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 361)
# Related Disease Score Top Affiliating Genes
1 intestinal pseudo-obstruction 32.6 FLNA RET SST
2 intestinal obstruction 32.4 FLNA GDNF MLN RET
3 hypoganglionosis 32.4 GDNF RET
4 irritable bowel syndrome 32.3 CCK HTR3A HTR4 MLN PYY SLC6A4
5 diarrhea 31.3 CCK HTR3A SST
6 megacolon 31.1 GDNF RET VIP
7 gastroesophageal reflux 30.7 CCK MLN PYY VIP
8 dyspepsia 30.7 CCK HTR3A SLC6A4 SST
9 gastroparesis 30.6 CCK HTR3A MLN
10 anismus 30.6 TAC1 VIP
11 colonic pseudo-obstruction 30.5 HTR4 KIT MLN SST
12 multiple endocrine neoplasia 30.4 CALCA GDNF RET
13 pain agnosia 30.4 CCK OPRM1 TAC1
14 carcinoid syndrome 30.3 CALCA HTR3A PYY SST
15 functional diarrhea 30.3 HTR3A HTR4 TAC1
16 gastrointestinal system disease 30.2 CCK HTR4 KIT MLN PYY SST
17 multiple endocrine neoplasia, type iib 30.1 CALCA GDNF RET
18 pheochromocytoma 30.0 CALCA GDNF RET SST VIP
19 eating disorder 30.0 CCK PYY SLC6A4
20 disease of mental health 29.8 CCK OPRM1 SLC6A4
21 thyroid cancer 29.8 CALCA GDNF KIT RET SST
22 outlet dysfunction constipation 12.3
23 coarse face hypotonia constipation 12.1
24 fecal incontinence 11.4
25 hirschsprung disease 1 11.4
26 opitz-kaveggia syndrome 11.4
27 pitt-hopkins syndrome 11.3
28 porphyria 11.3
29 parkinson disease, late-onset 11.3
30 sacral defect with anterior meningocele 11.3
31 colorectal cancer 11.2
32 hemorrhoid 11.2
33 celiac disease 1 11.2
34 neurogenic bowel 11.1
35 porphyria, acute hepatic 11.1
36 primary hyperparathyroidism 11.1
37 hypothyroidism 11.1
38 intestinal volvulus 11.1
39 adrenomyodystrophy 11.1
40 bartter disease 11.1
41 beriberi 11.1
42 disseminated peritoneal leiomyomatosis 11.1
43 ogilvie syndrome 11.1
44 pure autonomic failure 11.1
45 ulcerative proctitis 11.1
46 hashimoto thyroiditis 10.9
47 urofacial syndrome 1 10.9
48 fg syndrome 2 10.9
49 fg syndrome 4 10.9
50 neuropathy, hereditary sensory and autonomic, type vii 10.9

Graphical network of the top 20 diseases related to Constipation:



Diseases related to Constipation

Symptoms & Phenotypes for Constipation

GenomeRNAi Phenotypes related to Constipation according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 AQP3 CALCA CCK CLCN2 COL17A1 FLNA
2 Decreased viability GR00381-A-1 9.61 HTR3A MLN SLC6A4
3 Decreased viability GR00381-A-3 9.61 HTR3A MLN SLC6A4
4 Decreased viability GR00402-S-2 9.61 HTR3A MLN SLC6A4

MGI Mouse Phenotypes related to Constipation:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 AQP3 CLCN2 FLNA GDNF HTR3A HTR4
2 homeostasis/metabolism MP:0005376 10.28 AQP3 CCK CLCN2 FLNA HTR3A HTR4
3 growth/size/body region MP:0005378 10.17 AQP3 FLNA GDNF HTR3A HTR4 KIT
4 cardiovascular system MP:0005385 10.15 AQP3 CLCN2 FLNA GDNF KIT RET
5 digestive/alimentary MP:0005381 10.13 AQP3 CLCN2 FLNA GDNF KIT OPRM1
6 mortality/aging MP:0010768 10.13 AQP3 FLNA GDNF HTR3A HTR4 KIT
7 endocrine/exocrine gland MP:0005379 10.11 CCK CLCN2 GDNF HTR3A KIT OPRM1
8 immune system MP:0005387 10.07 AQP3 CLCN2 FLNA GDNF HTR3A KIT
9 nervous system MP:0003631 10.07 CCK CLCN2 FLNA GDNF HTR3A HTR4
10 normal MP:0002873 9.81 FLNA KIT OPRM1 PYY RET SLC6A4
11 renal/urinary system MP:0005367 9.56 AQP3 CCK GDNF HTR3A KIT PPOX
12 respiratory system MP:0005388 9.17 AQP3 FLNA HTR4 KIT NALCN RET

Drugs & Therapeutics for Constipation

Drugs for Constipation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 850)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-42-6 5284603
2
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 465-65-6 5284596
3
Diltiazem Approved, Investigational Phase 4,Phase 3,Phase 1 42399-41-7 39186
4
Acetylcholine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 51-84-3 187
5
Prucalopride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179474-81-8
6
Mirabegron Approved Phase 4,Phase 3 223673-61-8 9865528
7
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 103-90-2 1983
8
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
9
Amitriptyline Approved Phase 4,Not Applicable 50-48-6 2160
10
Cyclobenzaprine Approved Phase 4,Not Applicable 303-53-7 2895
11
Oxybutynin Approved, Investigational Phase 4,Phase 3,Not Applicable 5633-20-5 4634
12
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 137-58-6 3676
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 437-38-7 3345
14
Hydromorphone Approved, Illicit Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 466-99-9 5284570
15
Ketorolac Approved Phase 4,Phase 3,Not Applicable 66635-83-4, 74103-06-3 3826
16
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
17
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
18
Ketamine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 6740-88-1 3821
19
Hydrocodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 125-29-1 5284569
20
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-27-2 5288826
21
Orphenadrine Approved Phase 4 83-98-7 4601
22
Tramadol Approved, Investigational Phase 4,Phase 2 27203-92-5 33741
23
Gabapentin Approved, Investigational Phase 4,Phase 3,Not Applicable 60142-96-3 3446
24
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 93-14-1 3516
25
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7439-89-6, 15438-31-0 23925 27284
26
Ferrous fumarate Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 141-01-5
27
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 71273 175805
28
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
29
Dopamine Approved Phase 4,Phase 1,Phase 2,Not Applicable 62-31-7, 51-61-6 681
30
Ropinirole Approved, Investigational Phase 4 91374-21-9, 91374-20-8 5095 497540
31
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6 32051
32
Bisacodyl Approved Phase 4,Phase 3,Phase 2,Not Applicable 603-50-9
33
Naloxegol Approved Phase 4,Phase 3,Phase 2,Phase 1 854601-70-0
34
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 64-17-5 702
35
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 16590-41-3 5360515
36
Methylnaltrexone Approved Phase 4,Phase 2,Phase 3,Not Applicable 83387-25-1, 916055-93-1 6603824
37
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4618-18-2 11333
38
Linaclotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 851199-59-2 65351
39
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
40
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
41
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
42
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Not Applicable 138530-94-6, 103577-45-3 9578005
43
Lansoprazole Approved, Investigational Phase 4,Phase 2,Not Applicable 103577-45-3 3883
44
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 51-43-4 5816
45
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 329-65-7 838
46 Orange Approved Phase 4,Phase 2,Phase 3,Not Applicable
47
Calcium Carbonate Approved, Investigational Phase 4,Phase 2,Phase 3 471-34-1
48
Tropisetron Approved, Investigational Phase 4,Not Applicable 89565-68-4, 105826-92-4 5595
49
Loperamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53179-11-6 3955
50
Magnesium oxide Approved Phase 4,Phase 2,Not Applicable 1309-48-4 14792

Interventional clinical trials:

(show top 50) (show all 1687)
# Name Status NCT ID Phase Drugs
1 Lactobacillus Reuteri in Children With Constipation Unknown status NCT01388712 Phase 4
2 Polyethylene Glycol for Childhood Constipation Unknown status NCT01875744 Phase 4 Polyethylene glycol 4000
3 Improving Bowel Habits of Elderly With Probiotics and Non-probiotics Unknown status NCT02949882 Phase 4
4 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
5 Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section Unknown status NCT02571881 Phase 4 Oxycodone;oxycodone-naloxone
6 Pediatrics Anal Fissures Treatment With Polyethylene Glycol Unknown status NCT02419534 Phase 4 Polyethylene glycol;Polyethylene glycol with Diltiazem
7 Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
8 A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely Unknown status NCT00889655 Phase 4 Golytely (polyethylene glycol);MiraLax (polyethylene glycol 3350)
9 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
10 Prucalopride Prior to Small Bowel Capsule Endoscopy Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
11 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Unknown status NCT02095665 Phase 4 Mirabegron;Tamsulosin;Tylenol #3
12 Postoperative Pain After Intravenous Vitamin C Injection for Arthroscopic Rotator Cuff Repair Unknown status NCT02992028 Phase 4 Intravenous Nutrition (Vitamins) injection;Intravenous Saline injection
13 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
14 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
15 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
16 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
17 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
18 The Use of Iron Therapy for Patients With Anemia After Surgery Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
19 A Prospective Evaluation of the Strattice-LIFT to Treat Anal Fistula Unknown status NCT02423330 Phase 4
20 Transversus Abdominis Plane Blocks With Abdominoplasty Unknown status NCT01278264 Phase 4 Ropivacaine 0.25%, 0.5 ml/kg;Ropivacaine 0.25%, 0.5 ml/kg
21 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
22 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4 Mirapex ER
23 Probiotics in Newly Recognized Type 1 Diabetes Unknown status NCT03032354 Phase 4 Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12
24 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
25 The Therapeutic Effects of Insulin and Berberine on Stress Hyperglycemia Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
26 Anti-peristaltic Ileo-sigmoid Anastomosis for the Treatment of Slow-transit Constipation:Therapeutic Evaluation Completed NCT02147574 Phase 4
27 The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation Completed NCT03054805 Phase 4 Magnesium Oxide;MIYAIRI-BM
28 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo
29 To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation Completed NCT03060512 Phase 4 Polyethylene Glycol 3350;Movantik
30 Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications Completed NCT01096290 Phase 4 lubiprostone;Matched placebo
31 Methylnaltrexone Use for Opioid-induced Postoperative Constipation Completed NCT01773096 Phase 4 Methylnaltrexone;Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
32 Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years Completed NCT01424228 Phase 4 placebo;prucalopride
33 Soy Polysaccharide Fiber for the Treatment of Chronic Constipation in Children: a Randomized, Double-blind Trial Completed NCT01267370 Phase 4
34 Lactobacillus Reuteri DSM 17938 in Functional Constipation Completed NCT01244945 Phase 4
35 Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation Completed NCT02228616 Phase 4 Prucalopride;Polyethylene glycol (PEG);Lactulose
36 Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children Completed NCT01592734 Phase 4 Polyethylene glycol with electrolytes
37 Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness Completed NCT00672477 Phase 4 Methylnaltrexone;Placebo
38 The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study Completed NCT02726295 Phase 4 E. coli Nissle 1917(Mutaflor®);Placebo
39 Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation Completed NCT00153140 Phase 4 polyethyleneglycol3350
40 Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness Completed NCT00672139 Phase 4 Methylnaltrexone bromide
41 An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Completed NCT02590432 Phase 4 Linaclotide 290 micrograms;Linaclotide 145 micrograms;Linaclotide 72 micrograms
42 Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation Completed NCT00603681 Phase 4 Polyethylene glycol 4000;Polyethylene glycol 4000 with electrolytes
43 Lcr35 for Children With Functional Constipation Completed NCT01985867 Phase 4
44 The Effectiveness of Lubiprostone in Constipated Diabetics Completed NCT01170039 Phase 4 Lubiprostone;Placebo
45 Preference of Tegaserod vs. PEG 3350 in Patients With Constipation Completed NCT00171522 Phase 4 Tegaserod and Polyethylene Glycol 3350
46 Dietary Fiber Mixture in Constipated Pediatric Patients Completed NCT01333787 Phase 4
47 Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation Completed NCT00452335 Phase 4 Lubiprostone;Lubiprostone;Lubiprostone
48 Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation Completed NCT00149877 Phase 4 Tegaserod
49 A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC). Completed NCT01957046 Phase 4 Laxative
50 Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications Completed NCT00153127 Phase 4 polyethyleneglycol3350

Search NIH Clinical Center for Constipation

Cochrane evidence based reviews: constipation

Genetic Tests for Constipation

Genetic tests related to Constipation:

# Genetic test Affiliating Genes
1 Constipation 30

Anatomical Context for Constipation

MalaCards organs/tissues related to Constipation:

42
Colon, Lung, Breast, Kidney, Prostate, Testes, Liver

Publications for Constipation

Articles related to Constipation:

(show top 50) (show all 3200)
# Title Authors Year
1
Constipation, Antiepileptic drugs, and Gingivitis in Children and Adolescents with Cerebral Palsy. ( 30817037 )
2019
2
Visceral and Neural Manipulation in Children with Cerebral Palsy and Chronic Constipation: Five Case Reports. ( 30528865 )
2019
3
Functional anal canal length measurement using high-resolution anorectal manometry to investigate anal sphincter dysfunction in patients with fecal incontinence or constipation. ( 30637863 )
2019
4
Constipation with megacolon in a 36-year-old man: a rare presentation of MEN2B from Sri Lanka. ( 30642858 )
2019
5
Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study. ( 30643982 )
2019
6
Understanding the Changes in Diagnostic Criteria for Functional Constipation in Pediatric Patients: From Rome III to Rome IV. ( 30646474 )
2019
7
Functional Chronic Constipation: Rome III Criteria Versus Rome IV Criteria. ( 30646483 )
2019
8
Pelvic Floor Symptom Related Distress in Chronic Constipation Correlates With a Diagnosis of Irritable Bowel Syndrome With Constipation and Constipation Severity but Not Pelvic Floor Dyssynergia. ( 30646484 )
2019
9
Differential Effects of Lactobacillus casei Strain Shirota on Patients With Constipation Regarding Stool Consistency in China. ( 30646486 )
2019
10
Success and Complication Rates After Sacral Neuromodulation for Fecal Incontinence and Constipation: A Single-center Follow-up Study. ( 30646487 )
2019
11
Chinese herbal medicine for postpartum constipation: a protocol of systematic review and meta-analysis. ( 30647039 )
2019
12
Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation. ( 30649746 )
2019
13
Current State of Neuromodulation for Constipation and Fecal Incontinence in Children: A Systematic Review. ( 30650450 )
2019
14
A meta-analysis of naldemedine for the treatment of opioid-induced constipation. ( 30652502 )
2019
15
Mizagliflozin for the treatment of functional constipation: Are new drugs better? ( 30659835 )
2019
16
Effect of flaxseed or psyllium vs. placebo on management of constipation, weight, glycemia, and lipids: A randomized trial in constipated patients with type 2 diabetes. ( 30661699 )
2019
17
Constipation, diarrhea, and prophylactic laxative bowel regimens in the critically ill: A systematic review and meta-analysis. ( 30665795 )
2019
18
Effect of acupressure on constipation in patients with advanced cancer. ( 30675666 )
2019
19
Pharmacological and non-pharmacological treatments for opioid-induced constipation: A protocol for systematic review and network meta-analysis. ( 30681581 )
2019
20
Laxative effect of probiotic chocolate on loperamide-induced constipation in rats. ( 30716903 )
2019
21
Transcutaneous Neuromodulation at ST36 (Zusanli) is More Effective than Transcutaneous Tibial Nerve Stimulation in Treating Constipation. ( 30720579 )
2019
22
New Chronic Constipation Medication. ( 30721282 )
2019
23
Synergic Laxative Effects of a Herbal Mixture of Liriope platyphylla, Glycyrrhiza uralensis, and Cinnamomum cassia in Loperamide-Induced Constipation of Sprague Dawley Rats. ( 30724689 )
2019
24
Sex-related differences in resting-state brain activity and connectivity in the orbital frontal cortex and insula in patients with functional constipation. ( 30729624 )
2019
25
Colonic Stool Burden a Useful Surrogate for Slow Transit Constipation as Determined by a Radiopaque Transit Study. ( 30730352 )
2019
26
Electroacupuncture for Women with Chronic Severe Functional Constipation: Subgroup Analysis of a Randomized Controlled Trial. ( 30733966 )
2019
27
Constipation and laxative use among people living in nursing homes in 2007 and 2013. ( 30736737 )
2019
28
Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome. ( 30740753 )
2019
29
Constipation-induced pressor effects as triggers for cardiovascular events. ( 30761728 )
2019
30
Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy. ( 30774407 )
2019
31
Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. ( 30774946 )
2019
32
Protective effect of mulberry (Morus atropurpurea) fruit against diphenoxylate-induced constipation in mice through the modulation of gut microbiota. ( 30785176 )
2019
33
Things We Do for No Reason: Prescribing Docusate for Constipation in Hospitalized Adults. ( 30785419 )
2019
34
Pathophysiology and management of opioid-induced constipation: European expert consensus statement. ( 30788113 )
2019
35
Effect of acupressure on constipation in patients undergoing hemodialysis: A randomized double-blind controlled clinical trial. ( 30788281 )
2019
36
Should Children With Constipation Undergo Blood Lead Level Screening? ( 30789011 )
2019
37
Prucalopride for the treatment of constipation: a view from 2015 and beyond. ( 30791758 )
2019
38
Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis. ( 30791771 )
2019
39
Treating opioid-induced constipation in patients taking other medications: Avoiding CYP450 drug interactions. ( 30793348 )
2019
40
Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan. ( 30793431 )
2019
41
Anti-Inflammatory Response and Muscarinic Cholinergic Regulation during the Laxative Effect of Asparagus cochinchinensis in Loperamide-Induced Constipation of SD Rats. ( 30795644 )
2019
42
Anti-muscarinic drugs increase rectal compliance and exacerbate constipation in chronic spinal cord injury : Anti-muscarinic drug effect on neurogenic bowel. ( 30804425 )
2019
43
Hong Kong Chinese Medicine Clinical Practice Guideline for Cancer Palliative Care: Pain, Constipation, and Insomnia. ( 30805017 )
2019
44
Gut Microbiota and Chronic Constipation: A Review and Update. ( 30809523 )
2019
45
Carrying out a holistic assessment of a patient with constipation. ( 30811225 )
2019
46
The Relationship between Functional Constipation and Dietary Habits in School-Age Japanese Children. ( 30814410 )
2019
47
Prucalopride: A Recently Approved Drug by the Food and Drug Administration for Chronic Idiopathic Constipation. ( 30820411 )
2019
48
Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation. ( 30821019 )
2019
49
Understanding Constipation: A Cross-sectional Study from a Developing Country Setting. ( 30823961 )
2019
50
Preventive Effects of Different Fermentation Times of Shuidouchi on Diphenoxylate-Induced Constipation in Mice. ( 30832248 )
2019

Variations for Constipation

ClinVar genetic disease variations for Constipation:

6 (show all 14)
# Gene Variation Type Significance SNP ID Assembly Location
1 ARID1B NM_020732.3(ARID1B): c.4110G> A (p.Pro1370=) single nucleotide variant Conflicting interpretations of pathogenicity rs797045277 GRCh37 Chromosome 6, 157520041: 157520041
2 ARID1B NM_020732.3(ARID1B): c.4110G> A (p.Pro1370=) single nucleotide variant Conflicting interpretations of pathogenicity rs797045277 GRCh38 Chromosome 6, 157198907: 157198907
3 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh37 Chromosome 10, 43617416: 43617416
4 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh38 Chromosome 10, 43121968: 43121968
5 MT-TP; MT-TT m.15923A> G single nucleotide variant Uncertain significance rs1556424691 GRCh38 Chromosome MT, 15923: 15923
6 MT-TP; MT-TT m.15923A> G single nucleotide variant Uncertain significance rs1556424691 GRCh37 Chromosome MT, 15923: 15923
7 Translocation Likely pathogenic
8 46;XX;t(7;13)(p13;q34)dn Translocation Pathogenic
9 46;XY;t(9;11)(q34;p11.2)dn Translocation Pathogenic
10 46;XX;t(19;21)(q13.3;q22.3)dn Translocation Pathogenic
11 PPOX NM_000309.4(PPOX): c.1353T> G (p.Tyr451Ter) single nucleotide variant Pathogenic rs148292941 GRCh37 Chromosome 1, 161140885: 161140885
12 PPOX NM_000309.4(PPOX): c.1353T> G (p.Tyr451Ter) single nucleotide variant Pathogenic rs148292941 GRCh38 Chromosome 1, 161171095: 161171095
13 COL17A1 NM_000494.4(COL17A1): c.4145_4148del (p.Glu1382Alafs) deletion Pathogenic GRCh37 Chromosome 10, 105793710: 105793714
14 COL17A1 NM_000494.4(COL17A1): c.4145_4148del (p.Glu1382Alafs) deletion Pathogenic GRCh38 Chromosome 10, 104033953: 104033956

Expression for Constipation

Search GEO for disease gene expression data for Constipation.

Pathways for Constipation

GO Terms for Constipation

Cellular components related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 CLCN2 COL17A1 HTR3A HTR4 KIT OPRM1
2 extracellular region GO:0005576 9.85 CALCA CCK COL17A1 FLNA GDNF MLN
3 cell-cell junction GO:0005911 9.67 AQP3 COL17A1 FLNA KIT
4 perikaryon GO:0043204 9.63 CCK OPRM1 VIP
5 integral component of presynaptic membrane GO:0099056 9.58 HTR3A OPRM1 SLC6A4
6 integral component of postsynaptic membrane GO:0099055 9.5 HTR3A OPRM1 SLC6A4
7 axon GO:0030424 9.43 CALCA CCK HTR3A OPRM1 RET TAC1
8 neuronal cell body GO:0043025 9.17 CALCA CCK FLNA HTR3A RET SST
9 plasma membrane GO:0005886 10.21 AQP3 CLCN2 COL17A1 FLNA HTR3A HTR4

Biological processes related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.76 PPOX RET SLC6A4 SST
2 chemical synaptic transmission GO:0007268 9.67 HTR3A HTR4 SST TAC1
3 negative regulation of apoptotic process GO:0043066 9.61 FLNA GDNF VIP
4 G protein-coupled receptor signaling pathway GO:0007186 9.61 CALCA CCK HTR4 MLN OPRM1 PYY
5 neuropeptide signaling pathway GO:0007218 9.56 CALCA OPRM1 PYY TAC1
6 regulation of sensory perception of pain GO:0051930 9.5 CCK OPRM1 VIP
7 mRNA stabilization GO:0048255 9.48 GDNF VIP
8 enteric nervous system development GO:0048484 9.4 GDNF RET
9 response to pain GO:0048265 9.33 CALCA RET TAC1
10 regulation of signaling receptor activity GO:0010469 9.17 CALCA CCK GDNF MLN PYY SST

Molecular functions related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.5 GDNF KIT RET
2 peptide hormone receptor binding GO:0051428 9.26 CCK VIP
3 serotonin binding GO:0051378 9.16 HTR3A SLC6A4
4 neuropeptide hormone activity GO:0005184 9.13 CCK PYY VIP
5 hormone activity GO:0005179 9.1 CALCA CCK MLN PYY SST VIP

Sources for Constipation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....